首页> 外文期刊>Trials >SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX-trial): study design of an international multicenter randomized double-blinded controlled trial of high dose sodium-selenite administration in high-risk cardiac surgical patients
【24h】

SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX-trial): study design of an international multicenter randomized double-blinded controlled trial of high dose sodium-selenite administration in high-risk cardiac surgical patients

机译:SodiUm Selenite心脏手术中的给药(SUSTAIN CSX-trial):一项针对高危心脏手术患者高剂量亚硒酸钠给药的国际多中心随机双盲对照试验研究设计

获取原文
           

摘要

Background Cardiac surgery has been shown to result in a significant decrease of the antioxidant selenium, which is associated with the development of multiorgan dysfunction and increased mortality. Thus, a large-scale study is needed to investigate the effect of perioperative selenium supplementation on the occurrence of postoperative organ dysfunction. Methods/Design We plan a prospective, randomized double-blind, multicenter controlled trial, which will be conducted in North and South America and in Europe. In this trial we will include 1,400 high-risk patients, who are most likely to benefit from selenium supplementation. This includes patients scheduled for non-emergent combined and/or complex procedures, or with a predicted operative mortality of ≥5% according to the EuroSCORE II. Eligible patients will be randomly assigned to either the treatment group (bolus infusion of 2,000?μg sodium selenite immediately prior to surgery, followed by an additional dosage of 2,000?μg at ICU admission, and a further daily supplementation of 1,000?μg up to 10?days or ICU discharge) or to the control group (placebo administration at the same time points). The primary endpoint of this study is a composite of 'persistent organ dysfunction’ (POD) and/or death within 30?days from surgery (POD?+?death). POD is defined as any need for life-sustaining therapies (mechanical ventilation, vasopressor therapy, mechanical circulatory support, continuous renal replacement therapy, or new intermittent hemodialysis) at any time within 30?days from surgery. Discussion The SUSTAIN-CSX? study is a multicenter trial to investigate the effect of a perioperative high dosage sodium selenite supplementation in high-risk cardiac surgical patients. Trial registration This trial was registered at Clinicaltrials.gov (identifier: NCT02002247 ) on 28 November 2013.
机译:背景技术心脏手术已显示出抗氧化剂硒的显着降低,这与多器官功能障碍的发展和死亡率的增加有关。因此,需要进行大规模研究来研究围手术期补充硒对术后器官功能障碍发生的影响。方法/设计我们计划进行一项前瞻性,随机化的双盲,多中心对照试验,该试验将在北美和南美以及欧洲进行。在该试验中,我们将包括1,400位最有可能从补充硒中受益的高风险患者。其中包括计划进行非紧急联合和/或复杂手术的患者,或根据EuroSCORE II预计手术死亡率≥5%的患者。符合条件的患者将被随机分配到任一治疗组中(在手术前即刻推注2,000?μg亚硒酸钠,随后在ICU入院时再追加2,000?μg剂量,并每天额外补充1,000?μg,最多10剂量)天或重症监护病房出院)或对照组(在同一时间点服用安慰剂)。这项研究的主要终点是“持续器官功能障碍”(POD)和/或手术后30天内死亡(POD ++死亡)的综合结果。 POD定义为在手术后30天内的任何时间需要任何维持生命的疗法(机械通气,血管加压疗法,机械循环支持,连续肾脏替代疗法或新的间歇性血液透析)。讨论SUSTAIN-CSX?这项研究是一项多中心试验,旨在研究围手术期高剂量亚硒酸钠补充剂在高危心脏外科手术患者中的作用。试验注册该试验于2013年11月28日在Clinicaltrials.gov(标识:NCT02002247)上进行了注册。

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号